C. Ager

发表

Expanding the product profile of a microbial alkane biosynthetic pathway.

Matthew D. Smith, J. Siegel, I. S. Pultz, 2013, ACS synthetic biology.

Tumor hypoxia drives immune suppression and immunotherapy resistance

C. Ager, M. Curran, Pratha Budhani, 2015, Journal of Immunotherapy for Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Single-Cell RNAseq Analysis Reveals Robust, Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer

Xinzheng V. Guo, A. Califano, C. Drake, 2022, bioRxiv.

Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model

A. Califano, C. Drake, C. Abate-Shen, 2021, Cancer Immunology Research.

Cancer Therapy: Preclinical Activationof4-1BBonLiverMyeloidCellsTriggers Hepatitis via an Interleukin-27–Dependent Pathway

Manu Sebastian, D. Hong, C. Ager, 2018 .

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway

Manu Sebastian, D. Hong, C. Ager, 2018, Clinical Cancer Research.

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

D. Hong, C. Ager, M. Curran, 2019, Journal of Immunotherapy for Cancer.

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

K. Rajapakshe, C. Coarfa, Akash Boda, 2021, Journal for ImmunoTherapy of Cancer.

1154 High-potency synthetic STING agonists rewire myeloid subsets in the tumour microenvironment to dismantle immunosuppressive stroma in refractory pancreatic ductal adenocarcinoma

K. Rajapakshe, Akash Boda, C. Ager, 2022, Regular and Young Investigator Award Abstracts.

758 High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma

K. Rajapakshe, Akash Boda, C. Ager, 2021, Journal for ImmunoTherapy of Cancer.

329 Longitudinal immune profiling reveals unique myeloid and T cell phenotypes associated with spontaneous immunoediting in a novel prostate tumor model

A. Califano, C. Drake, C. Abate-Shen, 2020, Journal of Clinical and Translational Science.

Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.

Philip Jones, C. Ager, M. D. Di Francesco, 2019, Bioorganic & medicinal chemistry letters.

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

C. Drake, Somnath Tagore, S. Bansal, 2023, Journal for ImmunoTherapy of Cancer.

Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion

A. Regev, D. Schadendorf, B. Cleary, 2021, Nature Genetics.

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy

C. Ager, Nan Li, T. Zal, 2018, The Journal of clinical investigation.

The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity

D. Schadendorf, G. Schwartz, K. Wucherpfennig, 2022, bioRxiv.

Intratumoral STING Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy

C. Ager, 2018 .

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

Xinzheng V. Guo, Hu Li, C. Drake, 2020, Clinical Cancer Research.

Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages

Xinzheng V. Guo, A. Califano, E. Jonasch, 2021, Cell.

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

R. Davis, Jing Wang, Z. Ju, 2020, Cancer Immunology Research.

Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators

Christopher M. Jackson, A. Califano, C. Drake, 2022, bioRxiv.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

C. Ager, M. Curran, T. Bartkowiak, 2017, Cancer Immunology Research.

Mechanisms underlying 4-1BB agonist antibody mediated hepatotoxicity

C. Ager, M. Curran, Pratha Budhani, 2016, The Journal of Immunology.

Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

F. Meric-Bernstam, A. Naing, D. Hong, 2019, Journal of Clinical Oncology.

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.

D. Schadendorf, P. Shah, J. Marine, 2023, Cancer cell.

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

C. Drake, Somnath Tagore, S. Bansal, 2023, Journal for immunotherapy of cancer.

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

C. Ager, M. Curran, T. Bartkowiak, 2017, Cancer Immunology Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Hypoxia-activated prodrug and anti-angiogenic therapy cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration.

C. Ager, Arthur Liu, S. Gammon, 2023, JCI insight.

Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.

Christopher M. Jackson, A. Califano, C. Drake, 2023, Cancer cell.